Article Text

Rare disease
Melorheostosis and its treatment with intravenous zoledronic acid
  1. Rosemary Jane Hollick1,
  2. Alison Black1,
  3. David Reid2
  1. 1Aberdeen Royal Infirmary, Department of Rheumatology, Ward 3, Aberdeen Royal Infirmary, Aberdeen, AB25 2ZN, UK
  2. 2University of Aberdeen, Division of Applied Medicine, School of Medicine & Densitry, Aberdeen, AB25 2ZN, UK
  1. Correspondence to Rosemary Jane Hollick, rhollick{at}


We report a case of melorheostosis, a rare bone disorder characterised by mesodermal dysplasia, and its successful and prolonged treatment with the intravenous bisphosphonate zoledronic acid. The middle-aged man presented with pain and swelling of his tibia, which was diagnosed by imaging and bone biopsy as being due to melorheostosis. There was early symptom control after a single infusion of intravenous zoledronic acid. Prolonged symptom relief was accompanied by long-term suppression of the bone resorption marker β cross-laps. We suggest that melorheostosis can be treated with intravenous zoledronic acid and that treatment can be monitored by the use of a specific bone resorption marker.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Competing interests: None.

  • Patient consent: Patient/guardian consent was obtained for publication.